Antoni Torres1, Catia Cillóniz2, Francesco Blasi3, James D Chalmers4, Jacques Gaillat5, Nathalie Dartois6, Heinz-Josef Schmitt6, Tobias Welte7. 1. Department of Pulmonology, Hospital Clínic, Universitat de Barcelona, IDIBAPS, CIBERES, Barcelona, Spain. Electronic address: atorres@clinic.cat. 2. Department of Pulmonology, Hospital Clínic, Universitat de Barcelona, IDIBAPS, CIBERES, Barcelona, Spain. 3. Department of Pathophysiology and Transplantation, Università degli Studi di Milanoand Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center Fondazione IRCCS Cà Granda Ospedale, Maggiore Policlinico, Milano, Italy. 4. College of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK. 5. Infectious Diseases Department Centre Hospitalier Annecy Genevois, 1 avenue de l'Hôpital, 74374 Pringy, France. 6. Pfizer Vaccines, Medical and Scientific Affairs, 23-25 avenue du Dr. Lannelongue, F-75668 Paris Cedex 14, France. 7. Department of Respiratory Medicine, Medizinische Hochschule, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Abstract
BACKGROUND: The burden of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae (pneumococcus) among adults in Europe is poorly defined. METHODS: Structured searches of PubMed were conducted to identify the incidence of pneumococcal CAP among adults across Europe. RESULTS: The overall incidence rates for CAP was 68-7000 per 100,000 and the incidence in hospitalised CAP cases of all causes was 16-3581 per 100,000. In general the incidence of CAP increased consistently with age. Available data indicated higher burdens of pneumococcal CAP caused in groups with more comorbidities. Most cases of pneumococcal CAP (30%-78%) were caused by serotypes covered by PCV13 vaccine; the incidence of PCV13-related pneumonia decreased after the introduction of childhood vaccination. CONCLUSIONS: We observed a high burden adult pneumococcal CAP in Europe despite use of the 23-valent pneumococcal polysaccharide vaccine, particularly in elderly patients with comorbidities. CAP surveillance presented wide variations across Europe. Pneumococcal CAP has to be monitored very carefully due to the possible effect of current vaccination strategies.
BACKGROUND: The burden of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae (pneumococcus) among adults in Europe is poorly defined. METHODS: Structured searches of PubMed were conducted to identify the incidence of pneumococcal CAP among adults across Europe. RESULTS: The overall incidence rates for CAP was 68-7000 per 100,000 and the incidence in hospitalised CAP cases of all causes was 16-3581 per 100,000. In general the incidence of CAP increased consistently with age. Available data indicated higher burdens of pneumococcal CAP caused in groups with more comorbidities. Most cases of pneumococcal CAP (30%-78%) were caused by serotypes covered by PCV13 vaccine; the incidence of PCV13-related pneumonia decreased after the introduction of childhood vaccination. CONCLUSIONS: We observed a high burden adult pneumococcal CAP in Europe despite use of the 23-valent pneumococcalpolysaccharide vaccine, particularly in elderly patients with comorbidities. CAP surveillance presented wide variations across Europe. Pneumococcal CAP has to be monitored very carefully due to the possible effect of current vaccination strategies.
Authors: Catherine Hyams; Elizabeth Begier; Maria Garcia Gonzalez; Jo Southern; James Campling; Sharon Gray; Jennifer Oliver; Bradford D Gessner; Adam Finn Journal: BMJ Open Date: 2022-06-15 Impact factor: 3.006
Authors: Javier de-Miguel-Díez; Ana López-de-Andrés; Valentín Hernández-Barrera; José M de-Miguel-Yanes; David Carabantes-Alarcón; Zichen Ji; Jose J Zamorano-Leon; Rodrigo Jiménez-García Journal: Eur J Pediatr Date: 2022-04-25 Impact factor: 3.860
Authors: Freya Cools; Eveline Torfs; Juliana Aizawa; Bieke Vanhoutte; Louis Maes; Guy Caljon; Peter Delputte; Davie Cappoen; Paul Cos Journal: Front Microbiol Date: 2019-02-21 Impact factor: 5.640
Authors: Christian Theilacker; Ralf Sprenger; Friedhelm Leverkus; Jochen Walker; Dennis Häckl; Christof von Eiff; Julia Schiffner-Rohe Journal: PLoS One Date: 2021-06-15 Impact factor: 3.240
Authors: Lingye Chen; Bryan D Kraft; Victor L Roggli; Zachary R Healy; Christopher W Woods; Ephraim L Tsalik; Geoffrey S Ginsburg; David M Murdoch; Hagir B Suliman; Claude A Piantadosi; Karen E Welty-Wolf Journal: Am J Physiol Lung Cell Mol Physiol Date: 2021-06-09 Impact factor: 6.011